Trial watch: Cardiac glycosides and cancer therapy.

Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30

PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs (2014) 2.04

Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology (2014) 1.35

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07

Immunogenic cell death inducers as anticancer agents. Oncotarget (2014) 1.05

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01

Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

Digoxin use and the risk for colorectal cancer. Pharmacoepidemiol Drug Saf (2014) 0.82

Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells. Biosens Bioelectron (2014) 0.79

Plant derived substances with anti-cancer activity: from folklore to practice. Front Plant Sci (2015) 0.78

Influence of Sugar Amine Regiochemistry on Digitoxigenin Neoglycoside Anticancer Activity. ACS Med Chem Lett (2015) 0.77

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77

Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nat Commun (2016) 0.77

Recent biotechnological progress in enzymatic synthesis of glycosides. J Ind Microbiol Biotechnol (2013) 0.76

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia (2017) 0.75

Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins. Mol Ther (2016) 0.75

Time- and dose dependent actions of cardiotonic steroids on transcriptome and intracellular content of Na(+) and K(+): a comparative analysis. Sci Rep (2017) 0.75

Cardiac glycosides use and the risk of lung cancer: a nested case-control study. BMC Cancer (2014) 0.75

Downregulation of TGF-β Receptor-2 Expression and Signaling through Inhibition of Na/K-ATPase. PLoS One (2016) 0.75

Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by diverse growth factors. Br J Pharmacol (2017) 0.75

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature (1983) 5.80

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20

Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov (2008) 2.80

A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Cardiac glycosides as novel cancer therapeutic agents. Mol Interv (2008) 2.70

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2008) 2.09

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04

Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs (2000) 1.95

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene (2011) 1.87

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Digoxin in the management of cardiovascular disorders. Circulation (2004) 1.76

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75

Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta (2007) 1.70

Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63

Is digitalis a therapy for breast carcinoma? Oncol Rep (1999) 1.58

THE ROLE OF NA+ AND K+ IN THE OUABAIN-INHIBITION OF THE NA+ + K+-ACTIVATED MEMBRANE ADENOSINE TRIPHOSPHATASE. Biochim Biophys Acta (1965) 1.57

Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med (1982) 1.56

Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol (1980) 1.53

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer (2001) 1.50

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood (2007) 1.43

Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer (2009) 1.42

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33

Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets (2007) 1.31

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res (2007) 1.26

Cardiac glycosides and breast cancer, revisited. N Engl J Med (1982) 1.26

Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery (2008) 1.21

Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? Breast Cancer Res Treat (2005) 1.21

The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol (2007) 1.21

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19

Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses (1999) 1.17

Cardiac glycosides and breast cancer. Lancet (1979) 1.16

Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys (1988) 1.14

Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer (2003) 1.10

Up-regulation of Na(+),K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer. FEBS Lett (2004) 1.09

Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther (2009) 1.09

The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem (2004) 1.08

Endogenous ouabain in cardiovascular function and disease. J Hypertens (2009) 1.08

Digoxin use and the risk of breast cancer in women. J Clin Oncol (2011) 1.07

Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res (2008) 1.07

Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol (2006) 1.05

Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther (2011) 1.04

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00

The Na/K-ATPase-mediated signal transduction as a target for new drug development. Front Biosci (2005) 0.97

Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells. Toxicol Appl Pharmacol (2011) 0.92

Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs (2006) 0.92

Ouabain - the insulin of the heart. Int J Clin Pract (2010) 0.90

Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer (2011) 0.89

Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene (2004) 0.89

Alteration of sodium transport in mouse mammary epithelium associated with neoplastic transformation. Cancer Res (1978) 0.88

Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Res (2011) 0.88

Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep (2010) 0.88

Bidirectional ventricular tachycardia resulting from digoxin toxicity. J Cardiovasc Electrophysiol (2005) 0.86

Determinants of human and mouse melanoma cell sensitivities to oleandrin. J Exp Ther Oncol (2008) 0.85

Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett (2002) 0.85

Na/K-ATPase, endogenous digitalis like compounds and cancer development -- a hypothesis. Front Biosci (2005) 0.84

Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides. Am Heart J (1977) 0.84

Digoxin and hormone receptors. Lancet (1979) 0.84

Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer (2011) 0.82

Na+, K+-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines. Radiat Oncol Investig (1998) 0.81

Extracardiac and coronary vascular effects of digitalis. J Am Coll Cardiol (1985) 0.77

Digitalis: ions, inotropy and toxicity. N Engl J Med (1978) 0.76

William Withering revisited: 200 years of the foxglove. Am J Cardiol (1986) 0.76

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17

Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70